1. Howlader, N, Noone AM, Krapcho, M, et al. SEER cancer statistics review, 1975–2009, National Cancer Institute, Bethesda, MD. Available at http://seer.cancer.gov/csr/1975_2009_pops09/ Accessed December 2012.
2. Huggins C, Stephens RE, Hodges CV. Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate. Arch Surg. 1941;43:209–23.
3. NCCN clinical practice guidelines in oncology: prostate cancer. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf Accessed Jan 2013.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
5. US Food and Drug Administration: enzalutamide (XTANDI capsules). Available at http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm317997.htm Accessed Jan 2013.